Observations placeholder

Tolcapone (brand name Tasmar) is a drug used to treat Parkinson's disease (PD).

Adverse effects

Tolcapone has demonstrated significant hepatotoxicity that limits the drug's utility. Entacapone, another COMT inhibitor, is an alternative selection for levodopa adjunct therapy in the treatment of Parkinson's disease, largely since it has a more favorable toxicity profile.

This hepatoxicity can be attributed to elevated levels of transaminases, but studies have shown that minimal risk exists for those without preexisting liver conditions when their enzyme levels were being monitored. No clear mechanism is implicated in tolcapone induced liver toxicity, but it has been hypothesized that it has something to do with abnormal mitochondrial respiration due to the uncoupling of oxidative phosphorylation

Other side effects that result from the administration of tolcapone regard the increase in dopaminergic activity, digestive symptoms and liver function.[citation needed] Treatment with tolcapone runs the risk of eliciting or prolonging dyskinesia; this can be counteracted by decreasing the dose of levodopa. This occurs because the administration of tolcapone results in the accumulation of the biological methyl donor S-adenosyl-L-methionine (SAM) in the striatum that works to induce symptoms of PD.

Digestive symptoms include nausea, diarrhea, orthostatic hypotension, urine discoloration and dizziness Tolcapone causes more severe diarrhea than entacapone.

On Feb, 11, 2016: 1,083 people reported to have side effects when taking Tasmar. Among them, 59 people (5.45%) have Hallucination.

Time on Tasmar when people have Hallucination :

On Feb, 11, 2016: 1,083 people reported to have side effects when taking Tasmar. Among them, 5 people (0.46%) have Death.

Time on Tasmar when people have Death  :